Literature DB >> 14765378

Factors influencing survival in high-grade gliomas.

Jan C Buckner1.   

Abstract

Multivariate analyses have consistently identified a number of patient, tumor, and treatment variables that are significant prognostic factors for overall survival in patients with high-grade glioma. Age, performance status, mental status, tumor grade and histology, and extent of surgical resection are among the most significant prognostic factors influencing survival. Recently, we showed that normal versus abnormal baseline Folstein mini-mental status examination score is a significant prognostic factor in younger patients (age </=42), suggesting that mental status may be a more important determinant of clinical outcome than physical functioning in patients with high-grade glioma. Among tumor variables, tumor grade and histology appear to have the greatest effect on survival. A recursive partitioning analysis of three Radiation Therapy Oncology Group trials showed that among patients under 50 years of age, astrocytoma with anaplastic or atypical foci was associated with significantly improved survival compared with glioblastoma. An oligodendroglial component was also associated with improved survival in patients with grade 3 astrocytoma. In addition, combined loss of chromosome arms 1p and 19q is associated with improved chemosensitivity and overall survival in patients with pure oligodendroglioma. Among the treatment variables tested, extent of resection appears to be the most consistent prognostic factor. Gross total resection is associated with significantly improved survival compared with biopsy only. These models are capable of grouping patients into distinct prognostic subgroups with median survivals ranging from less than 5 to more than 50 months and thus provide useful information for future clinical trial design.

Entities:  

Mesh:

Year:  2003        PMID: 14765378     DOI: 10.1053/j.seminoncol.2003.11.031

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  144 in total

1.  Generation of polyclonal CMV-specific T cells for the adoptive immunotherapy of glioblastoma.

Authors:  Alexia Ghazi; Aidin Ashoori; Patrick J Hanley; Vita S Brawley; Donald R Shaffer; Yvonne Kew; Suzanne Z Powell; Robert Grossman; Zakaria Grada; Michael E Scheurer; Meenakshi Hegde; Ann M Leen; Catherine M Bollard; Cliona M Rooney; Helen E Heslop; Stephen Gottschalk; Nabil Ahmed
Journal:  J Immunother       Date:  2012 Feb-Mar       Impact factor: 4.456

2.  Hyperglycemia is independently associated with post-operative function loss in patients with primary eloquent glioblastoma.

Authors:  Thomas W Link; Graeme F Woodworth; Kaisorn L Chaichana; Stuart A Grossman; Robert S Mayer; Henry Brem; Jon D Weingart; Alfredo Quinones-Hinojosa
Journal:  J Clin Neurosci       Date:  2012-05-15       Impact factor: 1.961

3.  RAKE and LNA-ISH reveal microRNA expression and localization in archival human brain.

Authors:  Peter T Nelson; Don A Baldwin; Wigard P Kloosterman; Sakari Kauppinen; Ronald H A Plasterk; Zissimos Mourelatos
Journal:  RNA       Date:  2005-12-22       Impact factor: 4.942

4.  Survival following adjuvant PCV or temozolomide for anaplastic astrocytoma.

Authors:  Alba A Brandes; Linda Nicolardi; Alicia Tosoni; Marina Gardiman; Paolo Iuzzolino; Claudio Ghimenton; Michele Reni; Antonino Rotilio; Guido Sotti; Mario Ermani
Journal:  Neuro Oncol       Date:  2006-05-24       Impact factor: 12.300

5.  Treating high grade gliomas in the elderly: the end of ageism?

Authors:  Nitin Mukerji; Desiderio Rodrigues; Gill Hendry; Peter R C Dunlop; Fiona Warburton; Philip J Kane
Journal:  J Neurooncol       Date:  2007-11-17       Impact factor: 4.130

6.  Brain-skull contact boundary conditions in an inverse computational deformation model.

Authors:  Songbai Ji; David W Roberts; Alex Hartov; Keith D Paulsen
Journal:  Med Image Anal       Date:  2009-06-23       Impact factor: 8.545

7.  Establishing percent resection and residual volume thresholds affecting survival and recurrence for patients with newly diagnosed intracranial glioblastoma.

Authors:  Kaisorn L Chaichana; Ignacio Jusue-Torres; Rodrigo Navarro-Ramirez; Shaan M Raza; Maria Pascual-Gallego; Aly Ibrahim; Marta Hernandez-Hermann; Luis Gomez; Xiaobu Ye; Jon D Weingart; Alessandro Olivi; Jaishri Blakeley; Gary L Gallia; Michael Lim; Henry Brem; Alfredo Quinones-Hinojosa
Journal:  Neuro Oncol       Date:  2013-11-26       Impact factor: 12.300

8.  Adipose-derived stem cells as therapeutic delivery vehicles of an oncolytic virus for glioblastoma.

Authors:  Darnell T Josiah; Dongqin Zhu; Fernanda Dreher; John Olson; Grant McFadden; Hannah Caldas
Journal:  Mol Ther       Date:  2009-11-10       Impact factor: 11.454

9.  Effect of bexarotene on differentiation of glioblastoma multiforme compared with ATRA.

Authors:  Jin-Chul Heo; Tae-Hoon Jung; Sungjin Lee; Hyun Young Kim; Gildon Choi; Myungeun Jung; Daeyoung Jung; Heung Kyoung Lee; Jung-Ok Lee; Ji-Hwan Park; Daehee Hwang; Ho Jun Seol; Heeyeong Cho
Journal:  Clin Exp Metastasis       Date:  2016-03-08       Impact factor: 5.150

10.  A retrospective study of the safety of BCNU wafers with concurrent temozolomide and radiotherapy and adjuvant temozolomide for newly diagnosed glioblastoma patients.

Authors:  Edward Pan; Susan B Mitchell; Jerry S Tsai
Journal:  J Neurooncol       Date:  2008-04-04       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.